Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 relacorilant study in endogenous Cushing's syndrome
NL-OMON47012Phase 2Active, not recruiting
- Sponsor
- Corcept Therapeutics
- Start
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of relacorilant in Cushing's syndrome, sponsored by Corcept Therapeutics. Started Oct 2017; status: active, not recruiting.
02
Drugs
relacorilant
03
Conditions
Cushing's syndrome
Beyond the preview
Go deeper on NL-OMON47012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47012.